Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 5, 2012, Pages 1170-1175

  Sader, Helio S ^a   Paukner, Susanne ^b   Ivezic schoenfeld, Zrinka ^b   Biedenbach, Douglas J ^a   Schmitz, Franz J ^c   Jones, Ronald N ^a,d  

^a JMI LABORATORIES   (United States)

^b Nabriva Therapeutics Inc   (Austria)

^c KLINIKUM MINDEN   (Germany)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti infective development; Antimicrobial resistance; Haemophilus influenzae; Mycoplasma spp.; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BC 3781; CEFDINIR; CEFUROXIME; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; PENICILLIN G; UNCLASSIFIED DRUG; VANCOMYCIN;

AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; CHLAMYDOPHILA PNEUMONIAE; COMMUNITY ACQUIRED RESPIRATORY TRACT INFECTION; CONTROLLED STUDY; HAEMOPHILUS INFLUENZAE; LEGIONELLA PNEUMOPHILA; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; NONHUMAN; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; DITERPENES; HUMANS; MICROBIAL SENSITIVITY TESTS; RESPIRATORY TRACT INFECTIONS;

EID: 84859590529     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks001     Document Type: Article

References (16)

1. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27-72.
2. File TM. The science of selecting antimicrobials for communityacquired pneumonia (CAP). J Manag Care Pharm 2009; 15 Suppl 2: S5-11.
3. Novak R, Shlaes DM. The pleuromutilin antibiotics: a new class for human use. Curr Opin Investig Drugs 2010; 11: 182-91.
4. Bhavnani S, Hammel JP, Rubino CM et al. Pharmacokineticpharmacodynamic analysis for efficacy of BC-3781 using new clinical trial endpoints in patients with acute bacterial skin and skin structure infection. In: Abstracts of the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2011. Abstract A2-025. American Society for Microbiology, Washington, DC, USA.
5. Rubino CM, Xue B, Bhavnani S et al. Population pharmacokinetic analyses for BC-3781 using Phase 2 data. In: Abstracts of the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2011. Abstract A2-024. American Society for Microbiology, Washington, DC, USA.
6. Prince WT, Obermayr F, Ivezic-Schoenfeld Z et al. A Phase 2 study comparing the safety and efficacy of two doses of BC-3781 versus vancomycin in acute bacterial skin and skin structure infections (ABSSSI). In: Abstracts of the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2011. Abstract L-966. American Society for Microbiology, Washington, DC, USA.
7. Sader H, Farrell D, Biedenbach D et al. Antimicrobial activity of BC-3781, an investigational pleuromutilin, tested against organisms isolated from patients with community-acquired respiratory tract infections (CARTI) and acute bacterial skin and skin structure infections (ABSSSI). In: Abstracts of the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2011. Abstract C2-1798. American Society for Microbiology, Washington, DC, USA.
8. Wicha W, Ivezic-Schoenfeld Z, Novak R. Efficacy of BC-3781 in murine pneumonia models. In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract F1-2107. American Society for Microbiology, Washington, DC, USA.
9. Craig WA, Andes D, Ivezic-Schoenfeld Z et al. In vivo pharmacodynamic activity of BC-3781. In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract F1-2108. American Society for Microbiology, Washington, DC, USA.
10. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically- Eighth Edition: Approved Standard M07-A8. CLSI, Wayne, PA, USA, 2009.
11. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-first Informational Supplement M100-S21. CLSI, Wayne, PA, USA, 2011.
12. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 1.3, January 2011. http://www.eucast.org/clinical_breakpoints/ (18 March 2011, date last accessed).
13. Edelstein PH, Edelstein MA, Lehr KH et al. In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. J Antimicrob Chemother 1996; 37: 117-26.
14. Ruckdeschel G, Ehret W, Ahl A. Susceptibility of Legionella spp. to imipenem and 27 other b-lactam antibiotics. Eur J Clin Microbiol Infect Dis 1984; 3: 463-7.
15. EUCAST Discussion Document E. Dis 6.1. Antimicrobial susceptibility testing of intracelluar and cell-associated pathogens. March 2001. http://www.eucast.org/fileadmin/src/media/PDFs/2News_Discussions/3Discussion_Documents/E_Def_6_1_03_2001.pdf (11 January 2012, date last accessed).
16. Suchland RJ, Geisler WM, Stamm WE. Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob Agents Chemother 2003; 47: 636-42.